The clinical prognostic value of molecular intrinsic tumor subtypes in older breast cancer patients: A FOCUS study analysis
详细信息 查看全文
- 作者：Charla C. Engelsa ; Mandy Kiderlena ; b ; Esther Bastiaanneta ; b ; Antien L. Mooyaartc ; Ronald van Vlierberghea ; Vincent T.H.B.M. Smitc ; Peter J.K. Kuppena ; Cornelis J.H. van de Veldea ; G.J. Liefersa ; g.j.liefers@lumc.nl" class="auth_mail" title="E-mail the corresponding author
- 关键词：Breast cancer ; Molecular subtypes ; Elderly ; Clinical outcome ; Competing mortality ; Prognostication
- 刊名：Molecular Oncology
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：10
- 期：4
- 页码：594-600
- 全文大小：553 K
文摘
- •
Molecular intrinsic breast tumor subtypes were immunohistochemically determined in a large unselected older breast cancer cohort.
- •
Primary endpoint was Relapse Free Period, taking into account the competing risk of mortality, and relative survival.
- •
Patients with a Luminal A subtype had the lowest, patients with a Basal-like or ERBB2 subtype the highest risk of recurrence.
- •
The worst relative survival was observed for the ERBB2 subtype.
- •
This study supports the use of molecular subtyping in the older breast cancer patients for prognostication.